Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 838 results for score

  1. Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  2. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  3. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  4. Arteriovenous crossing sheathotomy for branch retinal vein occlusion (IPG334)

    Evidence-based recommendations on arteriovenous crossing sheathotomy for branch retinal vein occlusion. This involves cutting the sheath around the vessels and physically separating them where they cross to improve blood flow through the vein.

  5. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  6. Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse (IPG581)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair vaginal vault prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the vagina in place.

  7. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.

  8. MMprofiler for prognostic risk classification in multiple myeloma (MIB270)

    NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .

  9. Gastroelectrical stimulation for gastroparesis (IPG489)

    Evidence-based recommendations on gastroelectrical stimulation for gastroparesis. This involves using a stimulating device to send electrical impulses to the stomach muscles to help them work normally.

  10. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  11. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  12. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

  13. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

  14. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

  15. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.